Congleton Jon 4
4 · Mineralys Therapeutics, Inc. · Filed Apr 2, 2026
Research Summary
AI-generated summary of this filing
Mineralys CEO Jon Congleton Sells 75,000 Shares
What Happened
Jon Congleton, CEO of Mineralys Therapeutics (MLYS), sold a total of 75,000 shares in open‑market transactions on March 31, 2026, generating aggregate proceeds of approximately $1,970,522. The sale consisted of 19,364 shares at a weighted‑average price of $25.50 ($493,794), 55,183 shares at a weighted‑average price of $26.54 ($1,464,474), and 453 shares at a weighted‑average price of $27.05 ($12,254). These were sales (not purchases) and thus are generally considered liquidity moves rather than a direct bullish signal.
Key Details
- Transaction date: March 31, 2026; Form 4 filed April 2, 2026 (appears timely under the SEC two‑business‑day rule).
- Aggregate shares sold: 75,000; aggregate proceeds: ~$1.97 million.
- Reported prices (weighted averages): $25.50, $26.54, $27.05. Price ranges per filing: $25.00–$25.9994; $26.00–$26.9999; $27.00–$27.10. The filer can provide a per‑share price breakdown on request (see footnotes).
- Footnote: Transactions were effected pursuant to a Rule 10b5‑1 trading plan adopted December 30, 2025.
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
Context
- A 10b5‑1 plan allows insiders to sell according to a prearranged schedule and is commonly used to avoid questions about trading on inside information; it does not necessarily indicate a change in the insider’s view of the company.
- These were outright sales (transaction code S). For retail investors, purchases by insiders often carry more interpretive weight than routine sales executed under 10b5‑1 plans.
Insider Transaction Report
Form 4
Congleton Jon
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-03-31$25.50/sh−19,364$493,794→ 760,687 total - Sale
Common Stock
[F1][F3]2026-03-31$26.54/sh−55,183$1,464,474→ 705,504 total - Sale
Common Stock
[F1][F4]2026-03-31$27.05/sh−453$12,254→ 705,051 total
Footnotes (4)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.0000 to $25.9994. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.0000 to $26.9999. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.0000 to $27.1000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Signature
/s/ Adam Levy, Attorney-in-fact|2026-04-02